Growing literature suggests an important role of the GLP-1 system in AUD and the potential for this pharmacological target to be translated to humans, given the increasing use of GLP-1 analogues to treat type 2 diabetes mellitus and/or obesity. Here, GCG is linked to obesity due to melanocortin 4 receptor deficiency.